Final phase II results for sunitinib (SU) in Japanese pts with well-differentiated pancreatic neuroendocrine tumor (NET)

Authors
Category Primary study
JournalAnnals of Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 78df7205fc38b95c5b6d8b81820e4e90b3342772
First added on: Feb 07, 2025